Twelve-Month Effectiveness of Dupilumab on Eosinophilic Otitis Media in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps: A Multicenter Observational Study
American Journal of Rhinology & Allergy · 11.09.2026
DOI: 10.1177/19458924261480415 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Rhinology & Allergy, online erschienen am 11.09.2026. Verfasst von Cosimo Galletti und 19 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Surgery, Unit of Otorhinolaryngology, Umberto I Hospital, University Kore of Enna, Enna, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Eosinophilic otitis media (EOM) is a refractory type 2 inflammatory disease of the middle ear, frequently associated with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Conventional otologic treatments often provide incomplete or transient benefit. Because EOM and CRSwNP may share a type 2 inflammatory pathway involving the nasal, Eustachian tube, and middle-ear compartments, biologic therapy may offer benefit beyond sinonasal disease control. Long-term multicenter real-world data on dupilumab in patients with concomitant EOM and severe CRSwNP remain limited.
Objective
To evaluate the 12-month effectiveness of dupilumab on subjective and objective otologic outcomes in adults with EOM and severe CRSwNP.
Methods
In this multicenter observational cohort, 48 adults with severe CRSwNP and concomitant EOM, diagnosed according to Iino criteria, received dupilumab 300 mg every 2 weeks. Otologic outcomes included the Chronic Otitis Media Outcome Test 15 (COMOT-15; range 0-75) and tympanometry. Sinonasal outcomes, including Nasal Polyp Score, SNOT-22, and visual analog scale of nasal congestion, were secondary measures. Outcomes were evaluated at baseline, 6 months, and 12 months.
Results
Dupilumab was associated with progressive improvement in EOM-related outcomes. Median COMOT-15 decreased from 49 at baseline to 20 at 6 months and 15 at 12 months ( P < 0.0001). Tympanometry improved from 32 type B and 16 type C patterns at baseline to predominantly type A patterns at 12 months. Sinonasal outcomes also improved: median NPS decreased from 6 to 3 and 2, SNOT-22 from 68 to 28 and 22, and VAS nasal congestion from 8 to 2 and 1 at 6 and 12 months, respectively (all P < 0.0001). Peripheral eosinophil counts did not significantly decrease.
Conclusion
In patients with severe CRSwNP and concomitant EOM, dupilumab was associated with sustained 12-month improvement in EOM-related quality of life and tympanometric patterns, supporting further investigation within a one-airway-one-ear type 2 framework.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and Surgery, Unit of Otorhinolaryngology, Umberto I Hospital, University Kore of Enna, Enna, Italy.
- Department of Medical-Surgical Sciences and Advanced Technologies, E.N.T. Unit, P.O. "G. Rodolico", University of Catania, Catania, Italy.
- Otorhinolaryngology Section, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, Palermo, Italy.
- Department of Adult and Development Age Human Pathology "Gaetano Barresi", Unit of Otorhinolaryngology, University of Messina, Messina, ME, Italy.
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- Faculty of Medicine and Surgery, University Kore of Enna, Enna, Italy.
ORCID-Profile: Cosimo Galletti, Daniele Portelli
Zitieren
APA
Galletti, C., Stilo, G., Sireci, F., Giammona Indaco, F., Portelli, D., Barbieri, M. A., Frangipane, S., Giunta, G., Manzella, R., Ferrisi, M. G., Immordino, A., Maira, S., Maniaci, A., Ciodaro, F., Dispenza, F., Cocuzza, S., Galletti, F., Gallina, S., La Mantia, I., & Galletti, B. (2026). Twelve-Month Effectiveness of Dupilumab on Eosinophilic Otitis Media in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps: A Multicenter Observational Study. American Journal of Rhinology & Allergy. https://doi.org/10.1177/19458924261480415
Vancouver
Galletti C, Stilo G, Sireci F, Giammona Indaco F, Portelli D, Barbieri MA, et al. Twelve-Month Effectiveness of Dupilumab on Eosinophilic Otitis Media in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps: A Multicenter Observational Study. American Journal of Rhinology & Allergy. 2026. doi:10.1177/19458924261480415
BibTeX
@article{Galletti2026,
author = {Galletti, Cosimo and Stilo, Giovanna and Sireci, Federico and Giammona Indaco, Federica and Portelli, Daniele and Barbieri, Maria Antonietta and Frangipane, Silvia and Giunta, Giorgia and Manzella, Riccardo and Ferrisi, Maria Grazia and Immordino, Angelo and Maira, Salvatore and Maniaci, Antonino and Ciodaro, Francesco and Dispenza, Francesco and Cocuzza, Salvatore and Galletti, Francesco and Gallina, Salvatore and La Mantia, Ignazio and Galletti, Bruno},
title = {Twelve-Month Effectiveness of Dupilumab on Eosinophilic Otitis Media in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps: A Multicenter Observational Study},
journal = {American Journal of Rhinology & Allergy},
year = {2026},
doi = {10.1177/19458924261480415}
}
EUVIMED